You just read:

Once-Daily Edoxaban Evaluated in Two Subgroup Analyses of East Asian Patients from the Largest Comparative Phase 3 Trials of a Novel Oral Anticoagulant

News provided by

Daiichi Sankyo

24 Mar, 2014, 11:00 GMT